Across TCGA pan-cancer cohorts, NPIPB4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NPIPB4 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher NPIPB4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPIPB4 expression acts as an unfavorable survival marker.

CESC, OV, and GBM are the cancer types where NPIPB4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.091	0.830	<.001	36	view →
OV	DFS	Median	II,III,IV	0.209	0.541	.020	18	view →
GBM	DFS	Median	All	0.048	0.257	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NPIPB4 tumor-vs-normal RNA expression · all NPIPB4 data types